ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,537.02
      0.51%
      US Tech 100
      19,641.60
      0.83%
      Dow Jones
      39,308.00
      -0.06%
      Brent Oil
      87.08
      0.20%
      Bitcoin
      57,122.46
      -5.05%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Rubius Therapeutics Inc (RUBY)

      7. Rubius Therapeutics Inc (RUBY) News

      RUBY

      Rubius Therapeutics (RUBY)

      Rubius Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RUBY
      DateTimeSourceHeadlineSymbolCompany
      09/01/20219:00AMGlobeNewswire Inc.Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021NASDAQ:RUBYRubius Therapeutics Inc
      08/30/20218:00AMGlobeNewswire Inc.Rubius Therapeutics Appoints Jim Jogerst as Chief Business OfficerNASDAQ:RUBYRubius Therapeutics Inc
      08/20/20214:17PMEdgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:RUBYRubius Therapeutics Inc
      08/09/20218:22AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RUBYRubius Therapeutics Inc
      08/09/20218:11AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      08/09/20218:00AMGlobeNewswire Inc.Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateNASDAQ:RUBYRubius Therapeutics Inc
      07/29/20219:12AMDow Jones NewsRubius Therapeutics Taps Dannielle Appelhans as Chief Operating OfficerNASDAQ:RUBYRubius Therapeutics Inc
      07/29/20218:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      07/29/20218:00AMGlobeNewswire Inc.Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating OfficerNASDAQ:RUBYRubius Therapeutics Inc
      07/22/20218:30AMGlobeNewswire Inc.Rubius Therapeutics to Announce Second Quarter 2021 Financial ResultsNASDAQ:RUBYRubius Therapeutics Inc
      07/15/20218:00AMGlobeNewswire Inc.Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, ImmunotherapyNASDAQ:RUBYRubius Therapeutics Inc
      06/23/20214:01PMGlobeNewswire Inc.Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phas...NASDAQ:RUBYRubius Therapeutics Inc
      06/14/20217:52PMPR Newswire (US)Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Ch...NASDAQ:RUBYRubius Therapeutics Inc
      05/25/20216:00AMPR Newswire (US)Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological AgricultureNASDAQ:RUBYRubius Therapeutics Inc
      05/20/20218:30AMGlobeNewswire Inc.Rubius Therapeutics to Participate in Jefferies Virtual Healthcare ConferenceNASDAQ:RUBYRubius Therapeutics Inc
      05/19/20215:02PMGlobeNewswire Inc.Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers...NASDAQ:RUBYRubius Therapeutics Inc
      05/19/20219:01AMPR Newswire (US)Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus GreeningNASDAQ:RUBYRubius Therapeutics Inc
      05/13/20218:31AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      05/12/20218:00AMGlobeNewswire Inc.Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature CommunicationsNASDAQ:RUBYRubius Therapeutics Inc
      05/10/20218:00AMGlobeNewswire Inc.Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateNASDAQ:RUBYRubius Therapeutics Inc
      04/26/20218:00AMGlobeNewswire Inc.Rubius Therapeutics to Announce First Quarter 2021 Financial ResultsNASDAQ:RUBYRubius Therapeutics Inc
      04/12/20218:00AMGlobeNewswire Inc.Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive C...NASDAQ:RUBYRubius Therapeutics Inc
      04/09/20218:00AMGlobeNewswire Inc.Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid ...NASDAQ:RUBYRubius Therapeutics Inc
      03/30/20219:30AMPR Newswire (US)Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial OfficerNASDAQ:RUBYRubius Therapeutics Inc
      03/27/20218:42AMTipRanksRubius Therapeutics Charts A New Path For Hard-To-Treat CancersNASDAQ:RUBYRubius Therapeutics Inc
      03/18/20218:02AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
      03/18/20218:01AMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:RUBYRubius Therapeutics Inc
      03/17/20211:15AMTipRanksRubius Therapeutics: Promising Cancer Treatment Data De-Risks PipelineNASDAQ:RUBYRubius Therapeutics Inc
      03/16/20219:28PMGlobeNewswire Inc.Rubius Therapeutics Prices Upsized Public Offering of Common StockNASDAQ:RUBYRubius Therapeutics Inc
      03/15/20215:20PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:RUBYRubius Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:RUBY